anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
PURPOSE:To obtain an antitumor glycoprotein having desired molecular weight, easily, in high yield and purity, by degrading an antitumor glycoprotein having a molecular weight higher than a specific value with a reducing agent, and separating the objective protein from the treated liquid. CONSTITUTION:Antitumor glycoproteins having molecular weight of &gt;12,000 and obtained from the extraction liquid or supernatant liquid of cultured product of the reticuloendothelial cells, lymphoblasts, leukemia cells or fibroblasts of warm- blooded animal, is subjected to the degradation treatment with a reducing agent (e.g. a thiol compound such as 2-mercaptoethanol, a metal hydrogen complex such as sodium borohydride, a tertiary phosphine such as tri-n-butyl phosphine, etc.) and an antitumor glycoprotein having a molecular weight of 40,000-50.000, 12,000-17,000, and/or 7,000-9,000 are separated from the treated liquid. The yield is further improved by adding a surface active agent (e.g. SDS, Triton X, etc.) to the treating liquid.
PURPOSE:To obtain a diagnosing drug which can exactly and efficiently identify normal tissue and cancer tissue in the diagnosis of the cancer tissue by using a specific anti-human TV type collagen monoclonal antibody. CONSTITUTION:This diagnosing drug consists of the anti-human IV type collagen monoclonal antibody selected from the group consisting of JK199 and JK132. The JK199 intrinsically reacts specifically with all the human IV type collagens and specifically identifies the human IV type collagen degradation product having &gt;=5,000mol.wt. The JK132 intrinsically reacts specifically with all the human IV type collagens and does not identify the human IV type collagen degradation product of &lt;70,000mol.wt. reduced by 2-mercaptoethanol. This monoclonal antibody is preferably the human IV type collagen extracted from the tissue of the skin, kidney, placenta, etc., derived from man and is obtd. by fusing the immunocompetent cells obtd. by immunization of mammalian such as mouse with the subculturable myeloma cells and culturing the desired monoclonal antibody therefrom.
PROBLEM TO BE SOLVED: To obtain a cosmetic capable of hiding shape trouble of skin such as wrinkles, skin pores or roughness of texture and improving color tone trouble such as dermal stains or ephelides, excellent in persistence of effects and finishing the skin natural by including a silicon nitride having specific average particle diameter and a platy powder. SOLUTION: This cosmetic is obtained by including (A) a silicon nitride having 0.01-2 μm average particle diameter and (B) a platy powder (e.g. mucovite or biotite). The ingredients A and B preferably form a composite powder containing the ingredient A present on the surface of the ingredient B. The weight ratio of the ingredient A based on the sum total of the ingredients A and B is preferably 0.01-0.8. The average thickness of the ingredient B is &lt;=1 μm. The average particle diameter thereof is preferably 10-60 μm. The formulation amount of the sum total of the ingredients A and B formulated in the cosmetic is 2-90 wt.%. A powder such as silicic acid, silicic acid anhydride, magnesium silicate or kaolin can be used in the cosmetic.
The invention discloses an amber-containing Chinese medicine decoction piece composition preparation for somnolence. The amber-containing Chinese medicine decoction piece composition preparation is a compound Chinese medicine decoction piece preparation and comprises components in parts by mass as follows: 100 parts of amber, 100 parts of antelope&#39;s horns, 100 parts of radix codonopsis, 100 parts of poria cocos, 100 parts of radix polygalae and 100 parts of liquorice. The invention further discloses a preparation method of the amber-containing Chinese medicine decoction piece composition preparation for somnolence. The preparation method comprises steps as follows: raw materials are soaked, washed, dried, impacted, collided, rubbed, sheared, ground and broken, ultrafine amber powder with nano-scale of 1-65 nm is prepared, the soaking time is 35-40 minutes, the washing water pressure is 2-12 MPa, and the raw materials are embrittled at the temperature of subzero 19 DEG C before impacting. The invention further discloses an application package of the amber-containing Chinese medicine decoction piece composition preparation for somnolence. Amber, antelope&#39;s horns, radix codonopsis, poria cocos, radix polygalae and liquorice are proportionally packaged into bags. The amber-containing Chinese medicine decoction piece composition preparation has good effects on symptoms such as dizziness, malaise, palpitation and insomnia and the like.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composition for improving lowering of bloodstream of the skin and a composition for improving skin function each derived from stress, capable of effectively preventing and alleviating lowering of bloodstream of the skin and lowering of skin function derived from stress, free from adverse effect, being safe and capable of readily being administered and ingested and to provide foods and beverages using these compositions.  &lt;P&gt;SOLUTION: The composition for improving lowering of bloodstream of the skin derived from stress comprises fermented material of milk obtained by fermenting milk containing Lactococcus lactis subsp. cremoris FC (FERM AP-20185) as an active ingredient. The composition for improving the skin function comprises the fermented material of the milk as an active ingredient. The foods or the beverage are each obtained by using these compositions.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:To obtain a composite, capable of remarkably improving the redispersibility in water and dispersible therein with a low shearing force and providing a stable colloid without sandiness by blending fine cellulose with water-soluble natural gums, water-soluble synthetic gums and a hydrophilic substance according to a specific composition. CONSTITUTION:This composite is a dry composite, having a composition composed of water-soluble natural gums and water-soluble synthetic gums in the total amount (X pts.wt.) of 0.5-40 pts.wt. and a hydrophilic substance in an amount (Y pts.wt.) of 0-100 pts.wt. based on 100 pts.wt. fine cellulose and satisfying the formula 2X+Y&gt;=10. When redispersing the composite in water, the content of particles having &gt;=10mum size is &lt;=40% and the colloid fraction is &gt;=65%. The average particle diameter of the aqueous dispersion is &lt;=8mum and the content of particles having &gt;=10mum is especially preferably &lt;=5%. The redispersibility of the composite is remarkably improved by combining the water-soluble natural gums with the synthetic gums and the ratio of the natural gums to the synthetic gums is preferably within the range of (19:1) to (1:4), especially (19:1) to (1:1).
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a dispersion of an inorganic pigment typified by zinc oxide or titanium oxide, excellent in dispersibility and stability with the lapse of time, forming coat excellent in transparency and suitable especially for cosmetic use, and to provide a method for producing the dispersion.  &lt;P&gt;SOLUTION: The pigment dispersion comprises a solvent and 5-60 pts.wt. silicone having a reactive substituent per 100 pts.wt. inorganic pigment having 5-100 nm average primary particle diameter, wherein, when forming a film having 3 μm dry film thickness by using the pigment dispersion, the film has ≤5% haze. The method for producing the pigment dispersion comprises kneading a mixture of an inorganic pigment having 5-100 nm average primary particle diameter with a silicone having a reactive substituent by using two rolls, and dispersing the obtained kneaded product in a solvent, wherein the nonvolatile in the kneaded products is ≥75 wt.%.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
PURPOSE:To eliminate the harmful effect on the living body and to prolong the curing time by using a specific org. acid as a curing soln. in powder essentially consisting of tetracalcium phosphate and using tannin and tannin deriv. as a curing retarding agent. CONSTITUTION:The calcium phosphate essentially consisting of at least 4CP in 4CP and alpha-TCP is used as the essential material and the org. acid is used as the curing soln. At least one kind selected from the group consisting of the tannin, tannin deriv. and collagen is used as the curing retarding agent. One kind selected form the group consisting of citric acid, malic acid, malonic acid, glyeric acid and glutaric acid is used alone or &gt;=2 kinds thereof are used in combination as the org. acid. These org. acids form a hard cured material when the acids are intimately mixed with the calcium phosphate powder and are kneaded.
BACKGROUND AND PURPOSE: <p>This prospective study aimed to investigate diffe-rences in video head impulse test (vHIT) and&nbsp;cervical vestibular evoked myogenic poten-tial (cVEMP) findings between patients with vertebrobasilar insufficiency (VBI) and Meniere&rsquo;s disease (MD) who experience episodic vertigo attacks.</p>.
METHODS: <p>A total of 27 patients with VBI and 37 patients with MD were enrolled into the study in a tertiary referral center. Inclusion criteria consisted of patients with a minimum of two previous vertigo attacks, unaccompanied by any neurological symptoms during an attack. All patients underwent horizontal canal h-vHIT and c-VEMP assessments following pure sound audiometric examinations. First, vHIT and cVEMP results for low and high flow sides in VBI patients were analyzed. Subsequently, data from the low-flow side in VBI patients and the affected side in MD patients were compared.</p>.
RESULTS: <p>The mean vHIT values for low and high-flow volume sides in VBI patients were 0.68 and 0.88, respectively. In MD patients, mean vHIT values for affected and healthy sides were measured as 0.77 and 0.87, respectively. Abnormal results were observed in 66.7% of VBI patients and 51.4% of MD patients, with no statistically significant difference between the findings (p&gt; 0.05). Upon examining the affected side, c-VEMP responses were absent in 41% of MD patients and 48% of VBI patients, with no statistically significant difference between the groups (p&gt; 0.05).</p>.
CONCLUSION: <p>vHIT and cVEMP assessments can be utilized as supplementary tools to radiologic investigations for the clinical diagnosis and follow-up of VBI. However, no significant differences were observed between vHIT and cVEMP findings in patients with MD and VBI.</p>.
A composition of the present invention comprises a copolymer having silyl groups at least one reactive functional group bonded thereto. The copolymer preferably comprises, as one of constitutive monomers, Monomer (A) shown by the following Formula (I): &lt;CHEM&gt; wherein R1 is hydrogen atom or methyl; R2 alkylene group having 1-6 carbon atoms; and R3, R4 and R5 each is a reactive functional group which can cross-link molecules of the copolymer by hydrolyzing. Further, the copolymer preferably comprises, as a constitutive monomer, an alkyl (meth)acrylate and a siloxane-containing (meth)acrylate. The coat-forming method of the present invention comprises hydrolyzing the composition on a material to be treated to cross-link molecules of the copolymer,thereby forming a coat of the cross-linked copolymer having excellent resistance to washing. This coat can exhibit hair nature modifying effect, make-up retention improving effect, and skin-protecting effect. Also, it can impart water-repellency, unsusceptibility to fouling, suitability for sizing and crease resistance to fibers. Further, it can improve skin-cleaning effect, applicability, strippability and coat-strength of a peeling-off type cosmetic pack. &lt;IMAGE&gt;
Patient-specific clinical decision support is provided. When drug information is received, its relevance is determined based on received clinical information. If the drug information is relevant, an alert is communicated to the clinician. The alert may be a warning or may direct the clinician to perform an action related to patient care. A user interface is generated using the received drug and clinical information. A clinician may interact with the user interface by acknowledging or responding to various alerts. Clinical decision support is provided based on the relevancy of the drug information to the patient&#39;s clinical situation.
PROBLEM TO BE SOLVED: To obtain the subject agent excellent in preventing and treating effects on virus infectious diseases, effective for infection with retrovirus such as human immunodeficiency virus, comprising a compound having a specific structure as an active ingredient. SOLUTION: This agent comprises a compound of the formula (R is H or a hydroxyl group) or its acid addition salt as an active ingredient. For example, fasudil hydrochloride (namely, hexahydro-1-(5-isoquinolinesulfonyl)-1H-1,4- diazepine hydrochloride or its acid addition salt, etc., may be cited as the compound of the formula. The agent is prepared by mixing the active ingredient with a carrier such as gelatin, a saccharide, a starch or an isotonic sodium chloride solution. To be concrete, when the agent is made into an injection, 0.01-10wt.% of the active ingredient is dissolved in sterile water. The dose of the objective agent is preferably &gt;=2mg/kg daily in the case of parenteral administration and is preferably &gt;=4mg/kg daily in the case of oral administration.
PURPOSE:To obtain a prophylactic and therapeutic agent for an intimal hypertrophy of artery, particularly useful for a prophylaxis and therapy of a coronary restenosis after PTCA, having less adverse effect, containing 3- phenylthiomethylstyrene derivative as an effective component. CONSTITUTION:This agent contains a compound or its salt of formula (X is H, an alkoxy, a 1-5C alkyl, nitro, etc.; R&lt;1&gt; is H, a 1-3 alkyl or an acyl; R&lt;2&gt; is Hor a 1-5C alkyl; R&#39; is an amide, etc.; R&lt;4&gt; is cyano, an alkylsulfonyl, etc.; n is 1-5; m is 0-3). The compound of the formula having effects of anti-allergic, antitumor and tyrosine kinase inhibition, is useful in prophylaxis and treatment of an atherosclerosis, a restenosis after a percutaneous transluminal coronary angoiplasty (PTCA) and in prophylaxis and treatment of an intimal hypertrophy of artery accompanying to an indwelling stent. Its single dosage is 1-1000mg/kg, and its daily dosage is 20-4000mg/kg.
The present invention relates to the traditional Chinese medicine &#34;weichangshu&#34; for treating stomach and duodenal ulcer and chronic gastritis. In the prescription we select rhizome of Chinese goldthread, Chinese rhubarb etc. altogether 9 traditional Chinese medicinal herbs. The prepn. technology consists of volatile oil utilizing inclusion complex technology, the heating process changes into pressure reducing concentration and low temp. drying, the quality control adopting the monitoring of berberine hydrochloride and more than half of said medicament of the presoription. Said drug features good curative effect, small side effect, intensive raw material and toxicless.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for screening a prophylactic/therapeutic agent for arteriosclerosis.  &lt;P&gt;SOLUTION: The method for screening a compound or its salt for controlling expression fluctuation of an arteriosclerosis-related gene by modified LDL, a low-molecular compound or a protein contained in the modified LDL comprises using the arteriosclerosis-related gene. The kit for the screening the compound or its salt is provided. The compound or its salt for controlling the expression fluctuation of the arteriosclerosis-related gene obtained by using the screening method or the screening kit is obtained. The prophylaxis/therapeutic agent for arteriosclerosis contains the compound or its salt.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
FIELD: biotechnology, microbiology. SUBSTANCE: invention relates to the strain of lactobacillus showing ability to produce interferon in human unicellular cells and to effect on physiological and immunological processes in body. The strain Lactobacillus acidophilus N.V.EP 317/402 &#34;Narine&#34; TNCi is deposited in VKPM at N B-8017. The strain is obtained by of many years selection of the parent culture L. acidophilus N.V. 317/402 &#34;Narine&#34;. The strain is selected by its antibiotic activity to pathogens of gastroenteric diseases, resistance to antibiotics, vitamin producing capacity, growth rate and so on. Ferment of the strain L. acidophilus N.V.EP 317/402 &#34;Narine&#34; TNCi can be used for preparing dietetic and curative foodstuffs or for direct use in nutrition, as medicinal agent for treatment and prophylaxis of dysbacteriosis and its complications. EFFECT: strain indicated above, enhanced effectiveness of preparations. 4 dwg, 3 tbl, 2 ex
A craving control device comprising a housing, a craving input actuator supported by the housing, a wireless communicator supported by the housing, and a controller is provided. The craving input actuator can be configured to obtain information from a user pertaining to a timing, frequency, or intensity of a craving. The controller can be operatively connected to the craving input actuator and the wireless communicator to communicate craving information received by the craving input actuator via the wireless communicator to a device external to the housing. The device external to the housing can be a personal communication device. The housing can be sized and configured to be enclosed in the user&#39;s hand and or to be placed in a pocket of the user&#39;s clothing. Methods for using the craving control devices are also provided.
PURPOSE:To obtain an emulsified cosmetic having an excellent feeling in use and stability, capable of readily removing stain of cosmetic having oil and water repellency by dissolving a surfactant, an aqueous medium, a perfluoro organic compound and an ordinary liquid oil together in a fixed ratio. CONSTITUTION:An emulsified cosmetic comprising 0.01-20wt.% surfactant, 0.5-40wt.% aqueous medium, 30-90wt.% liquid perfluoro organic compound and 10-90wt.% liquid oil (e.g. squalane) except the liquid perfluoro organic compound. The total amounts of the perfluoro organic compound and the liquid oil is &gt;=60wt.%. The emulsified cosmetic is properly blended with components to be added to a common cosmetic and prepared by a conventional procedure to give the objective substance. The substance is applicable as a foundation cosmetic, a make-up cosmetic, a hair cosmetic, a medicinal cosmetic, an external preparation base and is especially suitable for cleansing cosmetic, massaging cosmetic, etc.
The present disclosure relates exposure notification, and in particular to techniques for verification of positive test results from public health authorities where individuals submit notice using public health approved mobile applications for exposure notification and/or contact tracing. When an individual attempts to submit a positive test result notification in a mobile application, the associated device&#39;s mobile number will be requested. This mobile number will then be sent a verification code to be entered in the application. At this point, these codes shall be stored digitally in escrow. A regular data feed from a health authority shall be provided that shall include an agreed encryption (irreversibly encrypted or reversibly encrypted) of the mobile numbers associated with any reported test. Any results submitted in the application that have a matching encryption of the mobile numbers shall be released from the escrow for subsequent notification.
PROBLEM TO BE SOLVED: To prepare a medicine-containing fat emulsion capable of improving the retentivity of the medicine in blood. SOLUTION: This medicine-containing fat emulsion comprises the medicine, an oily ingredient, an emulsifying agent and water. The emulsifying agent is a phospholipid having &lt;=5 iodine value and a hydrogenated egg yolk lecithin or soybean lecithin is cited. A phospholipid in which all of the fatty acid residues thereof are saturated fatty acid residues, preferably a glycerophospholipid of formula I or II, etc., (R&lt;1&gt; and R&lt;2&gt; are each a saturated fatty acid residue) is further cited. The amounts of the blended ingredients based on the fat emulsion are 0.01-10% (wt./vol.) phospholipid and 1-50%(wt./vol.) oily ingredient (e.g. soybean oil). The fat emulsion is preferably administered by injection, continuous drip infusion. etc., and intravenous administration is especially preferred.  A triacylglycerol which is a core part of fat particles hardly undergoes hydrolysis with a lipoprotein lipase, etc., and the fat emulsion is excellent in retentivity of the medicine in blood to sustain efficacies of the medicine.
PURPOSE:To obtain a yeast tablet useful as a digestive, by compounding titanium dioxide powder as a binder. CONSTITUTION:The tablet of dry yeast is prepared by compounding preferably 99.7-93.5wt% dry yeast powder with 0.3-5wt% titanium dioxide powder and 0-1.5wt% lubricant. The dry yeast is obtained by drying yeast to a water content of 2-8%, and the titanium dioxide used as the binder is fine powder having an average particle diameter of preferably &lt;=0.1mum, especially &lt;=0.03mum. The composition may contain various other assistants. For example, magnesium stearate, etc. can be used as a lubricant, lactose, rice bran, etc. as diluent or vehicle, and various digestive enzymes such as diastase, etc. and various vitamins, etc. as the active drug components. The tableting can be carried out by direct powder compression process.
Abstract A three component system and method for whitening teeth.  The first component is a pre-conditioning mouth rinse comprised of a dilute aqueous solution of acetic acid and N-L-alpha-aspartyl-L-phenylalanine methyl ester.   This component cleanses the pellicle film on the user&#39;s teeth and improves the uptake of molecular oxygen by the enamel from the second component which comprises a bleaching gel including hydrogen peroxide.  The preferred concentration of hydrogen peroxide is approximately six percent.  The third component is a polishing and pigmenting cream or paste that includes an abrasive substance and a pigmenting agent.  The abrasive agent is preferably an alumina silicate and the pigmenting agent is preferably titanium dioxide particles.
The present invention provides a method of increasing the efficacy of treating a muscle or sweat gland hyperactivity condition in a human or mammal with a neurotoxin. The method includes adding a quantity of either a diffusion-limiting agent or an anti-metabolic agent to the neurotoxin. Adding the agent to the neurotoxin leads to the formation of an agent/neurotoxin injection mixture. The quantity of agent added is sufficient to increase a therapeutic response of the human or mammal&#39;s sweat gland or muscle to the neurotoxin compared to what the response would have been had the human or mammal been treated with neurotoxin alone. The present invention provides a kit for treating a muscle or sweat gland hyperactivity condition in a human or mammal. The kit includes a needle, a solvent, a neurotoxin, and either a diffusion-limiting agent or an anti-metabolic agent.